WebSep 8, 2024 · Roche has signed a definitive merger agreement for the acquisition of US-based biopharmaceutical company Good Therapeutics for an upfront payment of … WebAbout. Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. Acquired by. Roche. Seattle, Washington, United States. 1-10. Series B. Private. www.goodtherapeutics.com.
Roche to acquire Good Therapeutics for $250M upfront …
WebSep 7, 2024 · Good Therapeutics – a RiverVest Venture Fund IV portfolio company – has entered into a definitive merger agreement to be acquired by Roche (SIX: RO, … WebSep 7, 2024 · Good Therapeutics Announces Acquisition of Conditionally Active PD-1-regulated IL-2 Program by Roche. September 7, 2024, 11:00 AM UTC. Share this … family watchdog ny
Roche to acquire Good Therapeutics for $250M upfront to …
WebRoche acquires Good Therapeutics to complement next generation PD1-IL2 therapeutics. April 21, 2024. Jasper Therapeutics Closes Transaction With Amplitude Healthcare Creating a Publicly Traded Biotechnology Company. April 19, 2024. Roche Venture Fund invests in the seed financing of Thelium Therapeutics. WebSep 7, 2024 · Roche will gain rights to Good's conditionally active, PD-1-regulated IL-2 program and an exclusive right to the platform technology to develop PD-1-regulated IL-2 receptor agonist therapeutics. WebSep 7, 2024 · The Swiss pharma group has agreed to buy Seattle-based biotech Good Therapeutics and its preclinical-stage PD-1-regulated IL-2 receptor agonist programme for $250 million upfront, with undisclosed ... cooper buckley ltd